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Highlights 
 Human Bocavirus 1 (HBoV1) was commonly detected in a survey of circa 13,000 
respiratory samples from the UK between 2015 and 2019 
 Co-infection with other viruses was observed in approximately three quarters of 
samples 
 However, mono-infection was also prevalent, and associated with clinically relevant 
disease 
 Intensive care was required in 31% of HBoV1 mono-infections and ventilation in 
17% 
 Fatal multi-organ failure was observed in an apparently HBoV1 mono-infected and 
















Since its first isolation in 2005, Human Bocavirus (HBoV) has been 
repeatedly associated with acute respiratory tract infections, 
although its role in pathogenicity remains unclear due to high co-
infection rates. 
Objectives 
To assess HBoV prevalence and associated disease in a cohort of 
respiratory patients in the East Midlands, UK between 2015 and 
2019. 
Study design 
We initially investigated the undiagnosed burden of HBoV in a 
retrospective paediatric cohort sampled between 2015 and 2017 
using an in-house PCR assay. HBoV was subsequently incorporated 
into the standard respiratory diagnostic pathway and we audited a 
calendar year of HBoV positive results between 2018 and 2019. 
Results 
Our retrospective PCR screening of previously routine diagnostic-
negative samples from juvenile patients identified a 9% (n=30) 
prevalence of HBoV type 1. These apparentHBoV1 mono-infections 











severe including ventilation, oxygen and steroid intervention with 
31% (n=9) of individuals requiring intensive care. When HBoV 
screening was subsequently adopted into the routine respiratory 
diagnostic pathway, year-round infections were observed in both 
children and adults peaking in February. 185 of 9098 (2.03%) 
individuals were found to be HBoV positive with children aged 12-24 
months the principally infected group. However, HBoV infection was 
also observed in patients aged over 60, predominantly as a mono-
infection. 23% of the 185 unique patients were HBoV 
monoinfectedand persistent low-level DNA positivity was observed 
in 15 individuals up to 6-months after initial presentation. 
Conclusion 
HBoV1 is a prevalent respiratory infection in the UK capable of 
causing serious monoinfections. 
Keywords 
Human Bocavirus; respiratory virus; viral co-infection; viral mono-infection; viral 
bronchiolitis; viral pneumonia  
 
Introduction 
Human Bocavirus 1 (HBoV1) was first identified in respiratory tract samples in 2005 
and three further genotypes (HBoV2, 3, and 4) were subsequently detected in faecal 
specimens [1-3]. HBoV types 1-4 were determined to be members of the Bocaparvovirus 











canine minute virus [4]. Despite HBoV1’s frequent detection in respiratory samples from 
subjects with acute respiratory tract infections (ARTIs), its role as a respiratory pathogen is 
not fully understood. High rates of co-infection (up to 70-80% in some studies) with 
predominantly Respiratory Syncytial Virus, Rhinovirus, Parainfluenza, Adenovirus [5, 6] and 
also frequent detection in asymptomatic subjects [7], have promoted a hypothesis of HBoV1 
as a “passenger” virus [5, 7, 8] . In vitro culture models of the virus have been described [9, 
10] which could further elucidate pathogenicity. 
Clinically, HBoV1 infections are typically characterized by mild self-limiting acute 
respiratory symptoms including cough, rhinitis, acute otitis media, and pharyngitis [7, 11]. 
However, possibly due to the unknown pathogenicity and frequently asymptomatic or self-
limiting nature of bocavirus infections, HBoV is often omitted from diagnostic investigation. 
Nevertheless, evidence to support HBoV1 as the aetiological agent in presentations of ARTI is 
growing, for instance by use of serological diagnosis using acute convalescent sera [12] and 
through correlation of HBoV1 viral loads with symptom severity in mono-infections [5, 11, 
13]. Furthermore, the virus has been associated with respiratory symptoms in the absence of 
other viral, fungal, or bacterial agents, with a significant detection rate difference between 
cases and controls [5]. HBoV1 has been associated not only with self-limiting upper 
respiratory tract infections, but also lower respiratory tract symptoms including wheezing, 
bronchiolitis, respiratory distress, and pneumonia [5, 8]. Indeed, there are several 
documented cases of bocavirus infection associated with severe lower respiratory illness 
requiring hospitalization, oxygen therapy, and even intensive care [14-17]. Taken together, 
these findings suggest HBoV1 can function in isolation as a respiratory pathogen. 
In order to better understand the epidemiology and disease burden (if any) imposed 
by HBoV infection, we retrospectively tested residual total nucleic acid (TNA) from 347 
nasopharyngeal aspirates (NPAs) by pan-bocavirus degenerate PCR [18]. Samples were 











age that were known to be negative for a panel of more established respiratory viruses. 
Having identified a significant number of bocavirus mono-infections associated with clinically 
severe disease, HBoV1 was included as a target in routine respiratory viral panel screening. 
HBoV1 detection was also reported throughout a calendar year (September 2018 to August 
2019) in upper and lower respiratory tract samples, again identifying significant numbers of 
patients infected with HBoV1, mainly children but also adults, encompassing both mono- and 
co-infections. Overall, our findings support the hypothesis that HBoV1 can be a significant 




Nasopharyngeal aspirates (NPA) from children between 6 months and 5 years old were 
processed for routine diagnostic investigation at Nottingham University Hospitals Trust 
(NUHT) between January 2015 and April 2017 as previously described [19].  TNAs negative 
for Human Adenovirus, Influenza (A and B), Human Metapneumovirus, Parainfluenza viruses 
(1–4), Rhinovirus, Coronavirus and Human Respiratory Syncytial Virus (RSV; A and B) were 
selected for bocavirus screening. TNAs were pooled in groups of 10 for initial screening and if 
positive, residual individual samples were retrospectively tested.  
A second study period (September 2018 to August 2019) investigated all respiratory 
samples (not limited by sample type or age) received for routine clinical diagnosis at NUHT. 
In this period, samples were routinely assessed with the AusDiagnostics Respiratory Viruses 
(16-well) target panel (REF 20602) for the High-Plex 24 system (REF 9150), including an 
HBoV target. Data were analysed using Microsoft Excel and Graphpad Prism software. Ethical 
approval for the use of residual material and association with anonymized patient information 













PCR assays  
TNA extracts were screened by PCR using pan-Bocaparvovirus genus primers panBOV-
F1 (TAATGCAYCARGAYTGGGTNGANCC) and panBOV-R1 (GTACAGTCRTAYTCRTTRAARCACCA) 
[20] to target the NS1 gene in 15 μl reactions comprising: 1.5 μl of QIAGEN 10x PCR buffer, 
3 pmol of each primer, 6 nmol of dNTPs, 0.375U QIAGEN HotStarTaq DNA polymerase, 1 μl 
of TNA template and nuclease-free water. PCR was thermocycled as follows: 95°C for 15 
minutes, then 55 cycles of 95°C for 20 seconds, 55°C for 20 seconds, and 72°C for 45 
seconds. Amplification of a 1798bp NS1 fragment was also performed as above, except with 
45 cycles and 72°C for 120 seconds, using novel primers hBocaNS1f 
(TCTCAACCTGCTTTYACYTATGT) and hBocaNS1r (AGAATTGTCAGCRSTATGAGSAA). All 
positive pools and individual samples were confirmed by agarose gel electrophoresis and 
sequencing as previously described [19]. Phylogenetic analysis of sequences was performed 
using MEGA7 software (version 7.0.25) and all human reference sequences were downloaded 
from GenBank circa May 2017.  
 
Results  
347 residual TNAs from NPAs collected January 2015 to April 2017 from individuals 
between 6 months and 5 years of age (negative for routinely screened viral pathogens) were 
identified and retrospectively screened for the presence of Bocavirus by degenerate, pan-
genus PCR in 35 pools. 19 pools were positive for Bocavirus and their component samples 
rescreened individually, identifying 30 (8.66%) TNAs positive HBoV1, representing 29 unique 
patients. Sample HBoV1 positivity was confirmed by Sanger sequencing and BLAST analysis, 
revealing circa 99% conservation with Genbank HBoV1 reference strains in the conserved 
298bp NS1/2 region targeted (data not shown).  











relatedness, a larger 1798 bp fragment of the NS1 gene was amplified from 20 of the 30 
positive samples. The products were sequenced from the 5’ end only, yielding 1170 bp from 
each patient (covering bases 366-1535 of the prototypical reference isolate NC007455, [1] 
and aligned with 196 reference sequences of HBoV1-4 downloaded from Genbank in May 
2017. Maximum likelihood phylogenetic reconstruction of this NS1 region confirmed strong 
bootstrap support for genotypic clustering of our positives with HBoV1 reference sequences 
(>0.99, data not shown). However, little support for any other phylogenetic inference was 
observed due to a high degree of genetic conservation observed in both study and reference 
HBoV1 sequences. 
Having identified the presence of previously undiagnosed HBoV1 infection in a 
significant proportion of NPA specimens investigated, clinical data in this pilot cohort were 
also retrospectively assessed (Table 1). All patients presented with a similar clinical picture 
of bronchiolitis variously including general respiratory distress, cough, coryza, and wheezing. 
38% (11 of 29) of patients received oxygen, 38% nebulisers and 17% (5 of 29) were 
supported by mechanical ventilation. No respiratory or systemic bacterial co-infections were 
identified, but 38% of patients were administered antibiotics. Furthermore, 31% (9 of 29) 
were admitted to intensive care, with one patient dying of multi-organ failure and viral 
pneumonitis. 
 
Table 1: Clinical and laboratory data from HBoV1 positive patients, Nottinghamshire, United 













Sample date Age group Hospital Care Ventilation Nebuliser Oxygen Steroids Bacterial Co-infection Antibiotics Additional care and notes 
1 Jan 2015 2-3 years Standard  Yes Yes Yes Negative Yes Severe RSV infection >2 years prior 
2 Jan 2015 6-12m Intensive Yes  Yes Yes Negative Yes IV salbutamol 
3 Jan 2015 6-12m Standard     unknown   
4 Jan 2015 6-12m Standard   Yes  Not tested for  Atrovent given, premature 
5 Feb 2015 4-5 years Standard     Negative Yes Prior gastrostomy 
6 Mar 2015 6-12m Intensive     Negative  Diarrhoea and vomiting, seizures, gastrostomy 
7 Mar 2015 6-12m Intensive  Yes   Negative   
8 Mar 2015 2-3 years Standard Yes Yes   Negative Yes Died of multi-organ failure and viral pneumonitis 
9 Mar 2015 6-12m Standard  Yes   Not tested for   
10 May 2015 13-24m Intensive    Yes Not tested for Yes Adrenaline, Cerebral Palsy 
11 Jun 2015 ≤6m Standard     Not tested for   
12 Oct 2015 13-24m Intensive Yes   Yes Negative Yes Salbutamol 
13 Nov 2015 6-12m Standard   Yes  Not tested for Yes  
14 Nov 2015 6-12m Intensive Yes Yes   Negative Yes Salbutamol 
15 Nov 2015 6-12m Standard   Yes  Not tested for   
16 Dec 2015 13-24m Standard   Yes  Negative Yes  
17 Dec 2015 ≤6m Intensive Yes    
E.coli (urine) 
Negative (blood) 
Yes Other viral infections before and after 
18 Jan 2016 13-24m Standard    Yes Not tested for   
19 Jan 2016 6-12m Standard     Negative  Salbutamol 
20 Feb 2016 2-3 years Standard  Yes   Not tested for   
21 Mar 2016 ≤6m Standard   Yes Yes Negative Yes Premature at 25 weeks 
22 Apr 2016 13-24m Standard  Yes Yes  Not tested for   
23 Jul 2016 2-3 years Standard   Yes  Not tested for  Salbutamol, Chemotherapy for Wilm's tumour 
25 Jul 2016 6-12m Intensive     Unknown  Subsequently Rhinovirus positive 
24 Aug 2016 13-24m Standard  Yes Yes  Not tested for   
26 Dec 2016 13-24m Standard  Yes Yes  Not tested for   
27 Feb 2017 6-12m Intensive     Unknown  
Multiple underlying comorbidities, other viral 











28 Feb 2017 6-12m Not admitted  Yes   Not tested for   











This retrospective in-house pilot study indicated a hidden HBoV1 burden of circa 9% 
in otherwise viral pathogen negative young children and encouraged the uptake of HBoV 
screening as part of routine diagnostic surveillance. Subsequently in August 2018 we began 
screening for HBoV in routine respiratory investigations using a commercial assay 
(AusDiagnostics) and undertook an audit of a calendar year of screening between 1st 
September 2018 and 31st August 2019. In this period 12,498 unique specimens were received 
for routine respiratory pathogen investigation, of which 208 (1.66%) were HBoV positive 
representing 185 of 9098 unique patients (2.03%). HBoV ranked 7th in viral prevalence behind 
Rhinovirus or Enterovirus (non-differentiated), Influenza A, RSV, Human Adenovirus, 
Parainfluenza Type 3 (PF3), Coronavirus and Human Metapneumovirus, but ahead of PF1, 
PF4, Parechovirus, PF2 and Influenza B (data not shown).  
Of the 208 positive specimens recorded, 165 (75.96%) were co-infected and 43 were 
from HBoV mono-infected patients (23.24%). Six mono- and 10 co-infected individuals were 
found to be HBoV positive during intensive care. Two of the 10 co-infected individuals had 
HBoV copy numbers 5- to 6-logs higher than the co-infecting virus. 
 116 (56%) of the 208 positive samples were throat swabs, 35% NPAs and 9% others 
including broncheoalveolar lavages, endotracheal aspirates and sputum. HBoV positivity rates 
by sample type were 73/1347 (5.42%) of NPAs, in contrast to only 116/10,249 (1.13%) of 
throat swabs and 19/902 (2.11%) of other samples received. Three individuals were sampled 
by both throat swab and NPA on the same or consecutive days. Two returned higher viral load 
values in the NPA (24- and 28-fold more viral target) whilst one indicated a 28-fold higher 
viral load in the throat swab compared to the NPA (data not shown). 
 To determine if HBoV1 infections were associated with seasonality, weekly HBoV 
positivity rates were investigated (Figure 1). Whilst HBoV positive samples were seen 
throughout the calendar year (commencing in week 36 of 2018 and finishing in week 35 of 
2019) a peak of positivity was observed around the middle of February (week 7 of 2019, 











suggesting a peak season from approximately the start of November 2018 until the end of 
April 2019. 
 
Figure 1: Weekly HBoV PCR positive samples recorded at NUHT between week 36 of 2018 
(commencing 1st September) and week 35 of 2019 (ending 31st August).  
 
Age of HBoV-infected individuals was significantly skewed toward the young (p=<0.0001, 
Chi-square test for trend), with 87% of unique HBoV-positive patients being aged 5 or under. 















Figure 2: Proportion of HBoV positive patients in first positive sample observed between 
weeks 36 of 2018 to 35 of 2019 grouped by age. 
 
Interestingly, of the 11 HBoV positive patients aged ≥60, seven were mono-infected and 
where co-infected, higher viral loads for HBoV were observed than for the co-infecting virus (data 
not shown). 
11 individuals were sampled on more than one occasion and  >1 day apart, ranging from 
a 13 to a 157 day period (Figure 3), all of whom were aged 5 years or under.  Three individuals 
were sampled on four separate occasions (patients 8 – 10, Figure 3), spanning 55, 91 and 104 





















































presenting with higher initial viral load of >105 (data points connected by solid lines, Figure 3), 
recorded their highest HBoV value on initial presentation, exhibiting a steady decline through the 
period of surveillance. Patient 8 initially presented with a viral load of 4.3x105, increasing by 
approximately one log to 3.3x106 (Figure 3) one week later having been transferred to an 
intensive care unit after initial assessment and sampling. Co-infection was observed at least one 
time point for all patients except one. However, in all six individuals presenting with HBoV values 
of ≥4x105, the HBoV viral load was higher than the co-infecting virus. 
 
Figure 3: HBoV viral load determined by the AusDiagnostics assay in patients sampled 
more than once, more than one day apart in weeks 36 of 2018 to 35 of 2019. 
 
Discussion  
Failure to detect viral pathogens responsible for ARTIs can lead to inconclusive 











a burden on local and global health and economy. In clinical settings, most antibiotic 
prescriptions are erroneously prescribed for respiratory illnesses caused mainly by viruses 
[21]. Such overuse not only contributes to bacterial resistance, but can also affect commensal 
gastrointestinal microbiota required for healthy gut function and potentially cause 
unnecessary adverse effects in patients [21, 22]. Expanding routine tested-for viral 
respiratory panels has the potential to reduce this public health burden. 
We tested this hypothesis by archiving and re-screening apparently viral-negative 
respiratory TNA extracts for HBoV, a relatively recently discovered, but widely reported viral 
pathogen, identifying 9% HBoV1 positivity of NPAs in patients aged 6 months to 5 years. 
Importantly, 10 (34%) patients with undiagnosed HBoV1 positive patients were prescribed 
empirical antibiotic therapy; eight in the absence of diagnosed bacterial co-infection whilst 
two were not investigated. 
 HBoV1 pathogenicity is not fully understood with HBoV frequently observed as a co-
infection. Our initial in-house study supported a causal role of HBoV1 as a respiratory 
pathogen, with severe symptoms observed and intensive care required in the absence of co-
infection with other typical viral or bacterial respiratory pathogens. Our subsequent one-year 
review of HBoV screening in routine diagnostic service confirmed previously observed high 
rates of co-infection with other viral pathogens. 
High rates of coinfections and the presence of HBoV1 in asymptomatic individuals could 
be explained by long persistence periods and high prevalence of the virus. HBoV1 was found 
to persist in mucosa for more than four months following primary infections, which increases 
the chances of co-existence with other viral or bacterial pathogens [23, 24] and the virus has 
been suggested to reactivate following a superinfection with another virus [4]. We similarly 
observed persistence of HBoV in our cohort for up to 6 months. HBoV1’s high prevalence could 
also explain the high rate of co-infections. One study estimated HBoV1 infection rate to be as 
high as 59% in a cohort of children with respiratory illness and another reported that ~90% 











persist for many months, and therefore the presence of such DNA does not necessarily 
indicate a recent infection. 
Our findings of frequent administration of oxygen, steroids and salbutamol in addition 
to ventilation and intensive care in HBoV1 mono-infection, supports previous reports of HBoV1 
as a cause of serious lower respiratory tract infections and pneumonia [5, 13-15].  
HBoV1 has been reported to have very low genetic diversity worldwide [18]. Our 
sequencing and phylogenetic analysis of a region of NS1 (circa 22% of the genome) indeed 
confirmed these findings and would indicate whole genome sequencing is required for more 
robust investigation and interpretation of epidemiology. Sequencing of this NS1 region did 
strongly suggest all detected samples were of HBoV type 1, but the possibility of 
recombination cannot be ruled out without whole genome sequencing [18].  
With respect to HBoV1 seasonality, our study showed higher prevalence during the 
late autumn and winter periods, consistent with prevalence reported worldwide [1, 26-28]. 
However, few studies reported year-round detection and two studies reported peak detection 
during summer [29-32]. The contradictory findings of these reports with many studies 
reporting winter and spring surges in HBoV1 infection rates could be explained by differences 
between strains isolated in different locations, but it could be also attributed to social or 
behavioural factors [33].  
In summary, our study implicates HBoV1 as a currently prevalent respiratory pathogen 
in the UK capable of causing serious mono-infections. Increasing adoption of this relatively 
newly described virus into established diagnostic screening panels could be helpful in aiding 
clinical management of patients with respiratory tract disease and reducing unnecessary 
prescribing of antibacterial agents. 
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